Myasthenia gravis: vizsgálatok itt: Japán
10 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Kobe, Minatoku, Sendai
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - 3. fázisTaking peopleA Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Kobe, Minatoku, Sendai
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00 - 3. fázisTaking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Chiba, Hanamaki, Hiroshima, Kawasaki-shi, Kita-gun, Kumamoto, Nagoya, Niigata, Nishinomiya-shi, Sapporo, Sendai, Shiwa-gun, tabashi City, Tokushima, Tokyo
- Életkor
- 18 év and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - 2/3. fázisTaking peopleA Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Where
- Azumino-shi, Chiba, Miyazaki, Nishinomiya-shi, Saitama Shi, Shinjuku-ku
- Életkor
- 2 év to 17 év
- People
- 12 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05265273 · EU 2022-502539-21-00 - 2. fázisTaking peopleADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Where
- Hanamaki, Sendai
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00 - No phaseTaking peopleADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Where
- Hanamaki, Kawasaki-shi, Narita, Sendai, Tsukuba
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07294170 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Chiba, Fukuoka, Hakodate-shi, Hanamaki-shi, Iruma-gun, Kita-gun, Koriyama-shi, Meguro-ku, Nagasaki, Narita-shi, Shinjuku-ku, Suita-shi
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 2. fázisTaking peopleADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Where
- Hanamaki, Kawasaki-shi, Narita, Sendai, Tsukuba
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00 - 4. fázisTaking peopleA Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
- Where
- Ibaraki, Kitakyushu-shi, Kumamoto
- Életkor
- 18 év and over
- People
- 75 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07221838 · EU 2025-522555-26-00 - 3. fázisTaking peoplePK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
- Where
- Saitama-shi
- Életkor
- 6 év to 17 év
- People
- 12 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT06607627 · EU 2024-515157-17-00